<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011539</url>
  </required_header>
  <id_info>
    <org_study_id>TepecikTRH-AKarabulut-001</org_study_id>
    <nct_id>NCT05011539</nct_id>
  </id_info>
  <brief_title>Thiol-disulfide Homeostasis in Patients With Ovarian Cancer</brief_title>
  <official_title>Thiol-disulfide Homeostasis in Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tepecik Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tepecik Training and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian cancer is the third most common after endometrial and cervical cancer in societies&#xD;
      with a high standard of living; It is the second most common type of gynecological cancer&#xD;
      after cervical cancer in societies with a low standard of living, and it is also the&#xD;
      deadliest among gynecological cancers. Dynamic thiol-disulfide homeostasis is an antioxidant&#xD;
      system that minimizes oxidative damage and prevents cell damage. In the presence of oxidative&#xD;
      stress, the thiol groups combine to form the disulfide structure, and when the oxidative&#xD;
      stress condition is over, they are separated into thiol groups again. This homeostasis is&#xD;
      impaired in conditions that cause oxidative processes such as diabetes, cardiovascular&#xD;
      diseases, cancers, rheumatoid arthritis, and chronic kidney failure. This can be determined&#xD;
      by measuring the total thiol and native thiol levels. Likewise, the level of ischemia&#xD;
      modified albumin increases in the case of oxidative stress. There are studies on this&#xD;
      homeostasis in the literature on many types of cancer; There are studies on endometrial&#xD;
      cancer and cervical cancer, which are gynecological cancers In this study, the usability of&#xD;
      these tests together with other diagnostic tests in the diagnosis of ovarian cancer will be&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>thiol - disulfide levels</measure>
    <time_frame>April 2021 - January 2021</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <description>The patients with ovarian cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ovarian cancer patients who applied to Izmir Tepecik Training and Research Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological diagnosis of ovarian cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having an acute or chronic disease that will cause oxidative stress&#xD;
&#xD;
          -  Using alcohol/cigarettes/drugs&#xD;
&#xD;
          -  Using antioxidant agents (such as vitamins A, C, E)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alaattin Karabulut, M.D.</last_name>
    <phone>+905548159443</phone>
    <email>alaattin_karabulut@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Izmir Tepecik Training and Research Hospital</name>
      <address>
        <city>İzmir</city>
        <state>Konak</state>
        <zip>35020</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaattin Karabulut</last_name>
      <phone>+905548159443</phone>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Sezgin B, Kinci MF, Pirinççi F, Camuzcuoğlu A, Erel Ö, Neşelioğlu S, Camuzcuoğlu H. Thiol-disulfide status of patients with cervical cancer. J Obstet Gynaecol Res. 2020 Nov;46(11):2423-2429. doi: 10.1111/jog.14480. Epub 2020 Sep 9.</citation>
    <PMID>32909381</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tepecik Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Alaattin Karabulut</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

